From Nasdaq: 2025-05-09 13:29:00

Veracyte, Inc. (VCYT) reported first-quarter 2025 earnings of 31 cents per share, a 63.2% increase from the previous year. Revenues rose 18.3% to $114.5 million, beating estimates. The company’s gross margin expanded to 69.5%. Veracyte reaffirmed its full-year testing revenue guidance. VCYT stock rose 1.2% post-earnings announcement.

The company’s testing revenues saw a 19% increase, driven by growth in Decipher and Afirma tests. Product revenues rose 1%, while biopharmaceutical and other revenues saw a 19% increase. Veracyte’s operating profit was $3.5 million, a significant improvement from the year-ago period.

Veracyte’s cash and cash equivalents were $186.1 million at the end of Q1 2025. The company reported a net cash provided from operating activities of $5.4 million. Veracyte currently holds a Zacks Rank #2 (Buy) and remains optimistic about its growth prospects for the year.

Other top stocks in the medical space include AngioDynamics (ANGO), Integer Holdings Corporation (ITGR), and Boston Scientific (BSX). ANGO reported strong earnings growth, while ITGR and BSX also exceeded expectations. These stocks are worth watching for potential investment opportunities in the healthcare sector.



Read more at Nasdaq: Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up